{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:58:21Z","timestamp":1792083501105,"version":"4.4.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/hco.0b013e328353b988","type":"journal-article","created":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T10:12:45Z","timestamp":1339063965000},"page":"429-440","source":"Crossref","is-referenced-by-count":7,"title":["Statins and kidney disease"],"prefix":"10.1097","volume":"27","author":[{"given":"Mark","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210204","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","article-title":"Lipoprotein metabolism and lipid management in chronic kidney disease.","volume":"18","author":"Kwan","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R2-18-20210204","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1525-1497.2004.40049.x","article-title":"Managing dyslipidemia in chronic kidney disease.","volume":"19","author":"Weiner","year":"2004","journal-title":"J Gen Intern Med"},{"key":"R3-18-20210204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.06300909","article-title":"Cardiovascular death in dialysis patients: lessons we can learn from AURORA.","volume":"5","author":"Sniderman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-18-20210204","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-personten-country panel.","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"R5-18-20210204","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Lipoproteins and Vascular Diseases Division Working Group on Best Practices: apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working groups on best practices.","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"key":"R6-18-20210204","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men.","volume":"14","author":"Schaeffner","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R7-18-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-140-1-200401060-00006","article-title":"The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease.","volume":"140","author":"Muntner","year":"2004","journal-title":"Ann Intern Med"},{"key":"R8-18-20210204","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.2009121285","article-title":"Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease.","volume":"21","author":"Contreras","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R9-18-20210204","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","article-title":"Association between serum lipids and survival in hemodialysis patients and impact of race.","volume":"18","author":"Kilpatrick","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R10-18-20210204","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"R11-18-20210204","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2215\/CJN.01450210","article-title":"Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease.","volume":"5","author":"Chawla","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-18-20210204","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1681\/ASN.2006060674","article-title":"Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome.","volume":"18","author":"Kovesdy","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R13-18-20210204","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/MNH.0b013e32834ad504","article-title":"Inflammation as a risk factor and target for therapy in chronic kidney disease.","volume":"20","author":"Miyamoto","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R14-18-20210204","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/sj.ki.5000446","article-title":"Characteristics of sudden death in hemodialysis patients.","volume":"69","author":"Bleyer","year":"2006","journal-title":"Kidney Int"},{"key":"R15-18-20210204","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R16-18-20210204","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention - an Intervention Trial Evaluating Rosuvastatin) trial.","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R18-18-20210204","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5551\/jat.3764","article-title":"Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study.","volume":"17","author":"Kimura","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"R19-18-20210204","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2215\/CJN.03380410","article-title":"Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.","volume":"5","author":"Ruggenenti","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-18-20210204","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.","volume":"53","author":"Koren","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R22-18-20210204","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"},{"key":"R23-18-20210204","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.ajkd.2008.05.027","article-title":"Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"52","author":"Rahman","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R24-18-20210204","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R25-18-20210204","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"R26-18-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria.","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Intern Med"},{"key":"R27-18-20210204","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease.","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"R28-18-20210204","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study.","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"R29-18-20210204","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.","volume":"14","author":"Tonelli","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R30-18-20210204","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRCBHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"R31-18-20210204","first-page":"386","article-title":"Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease Curr Opin Nephrol H","volume":"18","author":"Kalaitzidis","year":"2009","journal-title":"ypertens"},{"key":"R32-18-20210204","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2008.03.013","article-title":"Targeting proteinuria as a valid surrogate for individualized kidney protective therapy.","volume":"51","author":"de Zeeuw","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R33-18-20210204","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.","volume":"111","author":"Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"key":"R34-18-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5414\/CNP63245","article-title":"The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.","volume":"63","author":"Ozsoy","year":"2005","journal-title":"Clin Nephrol"},{"key":"R35-18-20210204","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","article-title":"The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.","volume":"21","author":"Atthobari","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R37-18-20210204","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R38-18-20210204","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis.","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R39-18-20210204","first-page":"321","article-title":"Do statins delay the incidence of ESRD in diabetic patients with moderate CKD J N","volume":"23","author":"Conley","year":"2010","journal-title":"ephrol"},{"key":"R40-18-20210204","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/01.ASN.0000133252.07149.05","article-title":"From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease.","volume":"15","author":"Afzali","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R41-18-20210204","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R42-18-20210204","first-page":"1381","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R43-18-20210204","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"R44-18-20210204","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2009.06.029","article-title":"Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.","volume":"54","author":"Krane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R45-18-20210204","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing haemodialysis.","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R46-18-20210204","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Schmieder R, for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"R47-18-20210204","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R48-18-20210204","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ki.2010.524","article-title":"Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction.","volume":"79","author":"Szummer","year":"2011","journal-title":"Kidney Int"},{"key":"R49-18-20210204","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ndt\/gfr599","article-title":"Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study).","volume":"27","author":"Razavian","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R51-18-20210204","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.02.047","article-title":"The scope of coronary heart disease in patients with chronic kidney disease.","volume":"53","author":"Hage","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R52-18-20210204","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2010090987","article-title":"Rosuvastatin in diabetic hemodialysis patients.","volume":"22","author":"Holdaas","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R53-18-20210204","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/ndt\/gfl095","article-title":"Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.","volume":"21","author":"Soveri","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R54-18-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R55-18-20210204","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a posthoc analysis.","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"R59-18-20210204","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1742-1241.2011.02789.x","article-title":"The ezetimibe Jonah: the trials and tribulations of an unlucky drug.","volume":"65","author":"Wierzbicki","year":"2011","journal-title":"Int J Clin Pract"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HCO.0b013e328353b988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T23:14:34Z","timestamp":1642374874000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001573-201207000-00018"}},"subtitle":["is the study of heart and renal protection at the cutting edge of evidence?"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e328353b988","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}